Mein Warenkorb

IGFBP-3

IGFBP-3 Molekülinformation

Englischer NameInsulin-like growth factor binding protein IIIAnzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel2Target-Alias
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Englischer NameInsulin-like growth factor binding protein III
Target-Alias
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel2
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical

IGFBP-3 Produktliste

  • Attribut

    Protein (2)

  • Produktbibliothek

    Online (2)

  • Spezies

    Human (2)

  • Etikett

    His Tag (1)Fc Tag (1)

  • Marker

    Unconjugated (2)

ProduktnummerSpeziesExpressionssystemProduktbeschreibungProteinstrukturReinheitEigenschaftenVorbestellen/Bestellen
Human
HEK293
Human IGFBP-3 (28-291) Protein, Fc Tag
In den Warenkorb legen
Human
HEK293
Human IGFBP-3 Protein, His Tag
In den Warenkorb legen
Gesamtmenge2
  • 1

IGFBP-3 Molekülhintergrund

Insulin-like growth factor-binding protein 3 is also known as IGFBP3, is a protein that, in humans, is encoded by the IGFBP3 gene. IGFBP3 forms a ternary complex of about 140 ~150 kDa with IGF1 or IGF2 and a glycoprotein insulin-like growth factor acid-labile subunit (ALS), thus alter the interaction of IGFs with their cell surface receptors. IGFBP3 exerts either proapoptotic or growth stimulatory effects depending upon the cellular context. Studies have shown that IGFBP3 can leads to the induction of apoptosis dependent or independent of the IGF-IGF receptor axis, accordingly acts as a negative regulator of tumorigenesis and progressing in certain carcinomas. The highest expression level is found in the nonparanchymal cells of the liver. Expression levels are also higher during extrauterine life and peak during puberty.

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
Mecasermin RinfabaterhIGF-I/rhIGFBP-3; TAK-607; OHB-607; IGF-I/IGFBP-3; SHP-607; HGT-ROP-001Phase 2 ClinicalInsmedBronchopulmonary Dysplasia; Cerebral Intraventricular Hemorrhage; Failure to Thrive; Laron Syndrome; Lung Diseases; Myotonic Dystrophy; Noonan Syndrome; Retinopathy of Prematurity
Details
ENT-001Ent-001; ENT-001; Ent001Phase 1 ClinicalOspedale San RaffaeleDiabetes Mellitus, Type 1; Inflammatory Bowel Diseases
Details
  • Molekülinformation
  • Produktliste
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns